Pharmaceutical Fill and Finish Outsourcing Market Report 2025

The pharmaceutical fill and finish outsourcing market size has grown strongly in recent years. It will grow from $3.53 billion in 2024 to $3.78 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the emergence of contract development and manufacturing organizations (CDMOs, demand for specialized services, shift to outsourced models, market expansion strategies, and stringent regulatory requirements.

The pharmaceutical fill and finish outsourcing market size is expected to see strong growth in the next few years. It will grow to $5.28 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to demand for specialized services, global market expansion, focus on core competencies, rapid market entry for new drugs, flexibility in manufacturing capacity, anticipated need for flexible manufacturing capacity to accommodate fluctuation. Major trends in the forecast period include increased biologics outsourcing, sustainability initiatives, geographic expansion of outsourcing hubs, technological integration for efficiency, rise in contract development and manufacturing organizations (CDMOs).

The increasing demand for biologic drugs is anticipated to drive the growth of the pharmaceutical fill and finish outsourcing market in the future. Biologic drugs, often referred to as biologics or biosimilars, are a category of pharmaceutical products derived from living organisms or containing components sourced from living organisms. By outsourcing the fill and finish phase of production, drug manufacturers can leverage the expertise and infrastructure of contract manufacturing organizations (CMOs). This enables pharmaceutical companies to concentrate on the development, research, and scaling of their biologic drugs while relying on CMOs for efficient and cost-effective fill and finish operations. For example, in September 2023, the Association for Accessible Medicines (AAM), a US-based trade association for manufacturers of generic prescription drugs and pharmaceutical chemicals, reported that in 2022, annual savings from biosimilar drugs exceeded $408 billion, reflecting a $35 billion increase compared to 2021. This trend indicates a consistent annual growth rate of 7-10 percent in savings in recent years. Therefore, the rising demand for biologic drugs is expected to boost the pharmaceutical fill and finish outsourcing market.

The rise in investments in biopharmaceutical research and development (R&D) is significantly fueling the growth of the pharmaceutical fill and finish outsourcing market. R&D investments refer to the financial resources allocated to activities aimed at discovering, developing, and eventually bringing new biopharmaceutical products to market. With a strong emphasis on innovation and drug development, pharmaceutical companies may increase their allocation of resources to research and development. Outsourcing fill and finish services allows these companies to redirect resources and investments toward core R&D activities. For instance, in January 2023, Roche Holding AG, a biopharmaceutical manufacturer based in Switzerland, announced a 3.7% increase in its R&D expenditure for 2022 compared to 2021. Consequently, the heightened investments in research and development by biopharmaceutical companies are driving the pharmaceutical fill and finish outsourcing market.

Product innovations represent a significant trend gaining traction in the pharmaceutical fill and finish outsourcing market. Companies within this sector are actively developing new and innovative products to maintain their competitive edge. For example, in January 2024, Stevanato Group, an Italy-based provider of drug containment and delivery solutions for the pharmaceutical and life sciences industries, introduced the EZ-fill Kit and a laboratory fill and finish service. The EZ-fill Kit is designed to streamline the filling process for small batches of injectable drugs, making it particularly beneficial during clinical trials and early commercial phases. This innovation helps pharmaceutical companies enhance small batch production, reduce costs, and accelerate time-to-market. Furthermore, the new non-GMP laboratory fill and finish service facilitates early evaluation of how the fill-and-finish process affects product performance. These innovations aim to improve efficiency and uphold high standards in drug development and production.

Leading companies in the pharmaceutical fill and finish outsourcing market are prioritizing the development of sustainable packaging materials and methods to reduce their carbon footprint and promote environmental conservation. Sustainable packaging involves creating and utilizing packaging that minimizes its environmental impact throughout its entire lifecycle. For instance, in November 2023, Amcor, an Australia-based pharmaceutical packaging company, launched next-generation HealthCare Recycle-Ready Medical Laminates. Amcor is producing all-film packaging that meets device application performance requirements while decreasing the overall carbon footprint of the final package and ensuring recyclability in the polyethylene stream. This solution features a polyethylene (PE) laminate that is a monomaterial suitable for various packaging formats, enabling it to replace non-recyclable lidding for 3D thermoformed packages with recyclable lidding for products such as drapes, protective materials, catheters, injection systems, and tubing systems.

In January 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, completed the acquisition of CinCor Pharma Inc. for $1.8 billion. This strategic move allows AstraZeneca to strengthen its cardiorenal portfolio by incorporating CinCor's promising compound, baxdrostat (CIN-107). Baxdrostat, an aldosterone synthase inhibitor (ASI), is designed to lower blood pressure in patients with treatment-resistant hypertension, including those with chronic kidney disease. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company specializing in kidney disease medications and treatments.

Major companies operating in the pharmaceutical fill and finish outsourcing market include Groninger and Co. GmbH, Merck and Co.Inc., Abbott Laboratories, Wockhardt Limited., Boehringer Ingelheim International GmbH, Becton Dickinson and Company, AbbVie Inc., Teva Pharmaceuticals Industries Ltd., Recipharm AB., Lonza Group AG, Catalent Inc., Dr. Reddys Laboratories Ltd., West Pharmaceutical Services Inc., Sun Pharmaceutical Industries Ltd., Patheon N.V., Piramal Enterprises Ltd., Gerresheimer AG, CordenPharma International, Fujifilm Diosynth Biotechnologies, Optima Packaging Group GmbH, Jubilant HollisterStier LLC., Ajinomoto Bio-Pharma Services, Cytovance Biologics Inc., Grand River Aseptic Manufacturing, Baxter Pharmaceutical Solutions LLC., Halo Pharma Inc., MabPlex Inc., August Bioservices.

North America was the largest region in the pharmaceutical fill and finish outsourcing market in 2024. The regions covered in the pharmaceutical fill and finish outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical fill and finish outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pharmaceutical fill and finish outsourcing involves the practice of contracting with specialized pharmaceutical manufacturing companies to provide services related to pharmaceutical filling and sealing operations into end-use containers with the required sterility and accuracy. This outsourcing is employed by pharmaceutical and biopharmaceutical companies to leverage specialized expertise, avoid the high costs associated with acquiring automated equipment, meet stringent regulatory agency standards, enhance efficiency, and gain flexibility in terms of production capacity.

The primary types of pharmaceutical fill and finish outsourcing products are liquids, solids, and semi-solids. Liquids refer to pharmaceutical formulations that are pourable and consist of a combination of active drug or chemical components and inert components. These formulations may be processed from organic substances isolated from animal origin, organic substances isolated from microorganisms, and inorganic substances. Pharmaceutical and biopharmaceutical companies commonly utilize these outsourcing services for their production needs.

The pharmaceutical fill and finish outsourcing market research report is one of a series of new reports that provides pharmaceutical fill and finish outsourcing market statistics, including pharmaceutical fill and finish outsourcing industry global market size, regional shares, competitors with a pharmaceutical fill and finish outsourcing market share, detailed pharmaceutical fill and finish outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical fill and finish outsourcing industry. This pharmaceutical fill-and-finish outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical fill and finish outsourcing market includes revenues earned by entities by providing outsourcing of aseptic or sterile filling and finishing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.